Show simple item record

dc.contributor.authorTopuz, Erkan
dc.contributor.authorTas, Faruk
dc.contributor.authorDerin, Duygu
dc.contributor.authorCamlica, Hakan
dc.contributor.authorGuney, Nese
dc.contributor.authorAydiner, Adnan
dc.date.accessioned2021-03-03T11:25:27Z
dc.date.available2021-03-03T11:25:27Z
dc.date.issued2007
dc.identifier.citationTas F., Derin D., Guney N., Camlica H., Aydiner A., Topuz E., "Addition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma", LUNG CANCER, cilt.57, sa.1, ss.79-83, 2007
dc.identifier.issn0169-5002
dc.identifier.otherav_27d00994-2460-4683-aca0-8595f97a11f3
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/31619
dc.identifier.urihttps://doi.org/10.1016/j.lungcan.2007.02.009
dc.description.abstractBackground: Topotecan is an active agent for the management of untreated and recurrent extensive-disease small cell tung cancer, (ED-SCLC). This study was designed to evaluate the efficacy and safety of a triplet combination with topotecan added to the standard PE regimen in previously untreated patients with ED-SCLC.
dc.language.isoeng
dc.subjectİç Hastalıkları
dc.subjectOnkoloji
dc.subjectSağlık Bilimleri
dc.subjectGöğüs Hastalıkları ve Allerji
dc.subjectDahili Tıp Bilimleri
dc.subjectTıp
dc.subjectSOLUNUM SİSTEMİ
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectONKOLOJİ
dc.titleAddition of topotecan to standard cisplatin/etoposide combination in patients with extended stage small cell lung carcinoma
dc.typeMakale
dc.relation.journalLUNG CANCER
dc.contributor.departmentİstanbul Üniversitesi , İstanbul Tıp Fakültesi , Dahili Tıp Bilimleri Bölümü
dc.identifier.volume57
dc.identifier.issue1
dc.identifier.startpage79
dc.identifier.endpage83
dc.contributor.firstauthorID183229


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record